Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2531 to 2540 of 2607 total matches.

Felbamate

   
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993  (Issue 910)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Felbamate (Felbatol - Wallace Laboratories), a phenyl dicarbamate structurally similar to meprobamate (Equanil, and others), was recently approved by the US Food and Drug Administration for use alone or with other drugs in adults with partial seizures with or without secondary generalization. It was also approved for use in addition to other drugs in children with the multiple types of seizures associated with the Lennox-Gastaut syndrome, a severe epileptic encephalopathy.
Med Lett Drugs Ther. 1993 Nov 26;35(910):107-8 |  Show IntroductionHide Introduction

Varicella Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 1995  (Issue 951)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
A live attenuated varicella vaccine (Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and embryonic guinea pig cell cultures.
Med Lett Drugs Ther. 1995 Jun 23;37(951):55-7 |  Show IntroductionHide Introduction

Vardenafil (Levitra) for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 2003  (Issue 1166)
al, European Urology Supplements 2002; 1:152, abstract 598). EDITOR: Mark Abramowicz, M.D. DEPUTY ...
Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.
Med Lett Drugs Ther. 2003 Sep 29;45(1166):77-8 |  Show IntroductionHide Introduction

Tattoo Removal

   
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003  (Issue 1170)
for tattoo removal (EL Tanzi et al, J Am Acad Dermatol 2003; 49:1). The wavelengths emitted by these lasers ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).
Med Lett Drugs Ther. 2003 Nov 24;45(1170):95-6 |  Show IntroductionHide Introduction

Stalevo for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
doses of levodopa/carbidopa (100/25) plus entacapone (RA Hauser, Neurology 2004; 62 suppl 1:S64 ...
Levodopa combined with carbidopa (Sinemet, and others) is the most widely used treatment for patients with Parkinson's disease, but after 2 to 5 years most patients develop troublesome complications (Treatment Guidelines from The Medical Letter 2004; 2:41). The newest treatment for Parkinson's disease patients with end-of-dose "wearing-off" is Stalevo (Novartis), a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone (Comtan) with 3 different doses of levodopa/carbidopa. The rationale for Stalevo is that it permits some patients to take only one pill rather than...
Med Lett Drugs Ther. 2004 May 10;46(1182):39-40 |  Show IntroductionHide Introduction

Addendum: Dermal Fillers

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007  (Issue 1265)
-mail your request to: permissions@medicalletter.org Subscriptions (US): 1 year - $89; 2 years - $151 ...
Some Medical Letter consultants have suggested that our recent article on dermal fillers (Med Lett Drugs Ther 2007; 49:39) should have included stronger warnings about the risk of fillers that are not biodegradable, such as Artefill. The polymethylmethacrylate (PMMA, the same material that makes up Plexiglas) beads in Artefill can over time, even with the best technique, cause foreignbody granulomas and hypertrophic scarring, which may require surgical removal. Granulomas and nodules have been especially frequent when Artefill was injected into the lips. Complications are less likely with...
Med Lett Drugs Ther. 2007 Jul 16;49(1265):59 |  Show IntroductionHide Introduction

Deep Brain Stimulation for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009  (Issue 1309)
DISEASE — Medical therapy is effective for initial treatment of Parkinson’s disease. 1 Surgery should ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Med Lett Drugs Ther. 2009 Apr 6;51(1309):26-7 |  Show IntroductionHide Introduction

Table: Safety of Drugs for IBD in Pregnancy (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
disease; JAK = Janus kinase; TNF = tumor necrosis factor 1. U Mahadevan et al. Gastroenterology 2019; 156 ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113   doi:10.58347/tml.2023.1680b |  Show IntroductionHide Introduction

Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
illness ▪ FDA-approved for chemoprophylaxis of influenza in patients ≥1 year old $27.00 152.00 ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5   doi:10.58347/tml.2024.1717d |  Show IntroductionHide Introduction

H. Influenzae Vaccine For Infants

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991  (Issue 836)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Med Lett Drugs Ther. 1991 Jan 25;33(836):5-7 |  Show IntroductionHide Introduction